-$0.47 Earnings Per Share Expected for Verona Pharma plc (NASDAQ:VRNA) This Quarter

Brokerages predict that Verona Pharma plc (NASDAQ:VRNAGet Rating) will report ($0.47) earnings per share for the current quarter, Zacks reports. Zero analysts have issued estimates for Verona Pharma’s earnings, with the highest EPS estimate coming in at ($0.46) and the lowest estimate coming in at ($0.48). Verona Pharma reported earnings per share of ($0.55) in the same quarter last year, which would suggest a positive year-over-year growth rate of 14.5%. The firm is scheduled to announce its next earnings report before the market opens on Monday, January 1st.

Zacks’ EPS calculations are a mean average based on a survey of sell-side analysts that follow Verona Pharma.

Verona Pharma (NASDAQ:VRNAGet Rating) last issued its quarterly earnings results on Thursday, March 3rd. The company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.50) by $0.10.

Several equities analysts have commented on VRNA shares. Zacks Investment Research upgraded shares of Verona Pharma from a “hold” rating to a “buy” rating and set a $5.50 price target on the stock in a research note on Wednesday, April 6th. HC Wainwright reissued a “buy” rating and issued a $25.00 price objective on shares of Verona Pharma in a report on Tuesday, January 25th.

NASDAQ VRNA opened at $3.90 on Tuesday. The company has a debt-to-equity ratio of 0.03, a current ratio of 5.09 and a quick ratio of 5.09. The stock has a market capitalization of $235.44 million, a P/E ratio of -2.91 and a beta of 0.60. The firm’s 50-day moving average is $4.80 and its two-hundred day moving average is $5.35. Verona Pharma has a 12 month low of $3.66 and a 12 month high of $7.87.

In other news, CEO David Zaccardelli sold 52,056 shares of the stock in a transaction that occurred on Thursday, February 3rd. The stock was sold at an average price of $0.73, for a total transaction of $38,000.88. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Kathleen A. Rickard sold 112,800 shares of the stock in a transaction that occurred on Friday, April 8th. The shares were sold at an average price of $0.59, for a total value of $66,552.00. Following the transaction, the insider now owns 2,606,128 shares of the company’s stock, valued at $1,537,615.52. The disclosure for this sale can be found here. In the last quarter, insiders have sold 234,992 shares of company stock valued at $144,718. 3.90% of the stock is currently owned by company insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Geode Capital Management LLC boosted its stake in Verona Pharma by 24.0% during the fourth quarter. Geode Capital Management LLC now owns 13,273 shares of the company’s stock valued at $89,000 after buying an additional 2,566 shares in the last quarter. Morgan Stanley lifted its stake in Verona Pharma by 123.0% in the 3rd quarter. Morgan Stanley now owns 8,194 shares of the company’s stock worth $45,000 after acquiring an additional 4,520 shares in the last quarter. D.A. Davidson & CO. raised its stake in shares of Verona Pharma by 20.0% during the 4th quarter. D.A. Davidson & CO. now owns 48,000 shares of the company’s stock worth $323,000 after purchasing an additional 8,000 shares in the last quarter. Lindbrook Capital LLC purchased a new stake in shares of Verona Pharma during the 4th quarter worth about $67,000. Finally, IPG Investment Advisors LLC bought a new position in shares of Verona Pharma in the 4th quarter valued at approximately $80,000. 61.19% of the stock is currently owned by hedge funds and other institutional investors.

About Verona Pharma (Get Rating)

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.

Recommended Stories

Get a free copy of the Zacks research report on Verona Pharma (VRNA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Verona Pharma (NASDAQ:VRNA)

Receive News & Ratings for Verona Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verona Pharma and related companies with MarketBeat.com's FREE daily email newsletter.